Identification of Two Subsets of Murine DC1 Dendritic Cells That Differ by Surface Phenotype, Gene Expression, and Function
Classical dendritic cells (cDCs) in mice have been divided into 2 major subsets based on the expression of nuclear transcription factors: a CD8 + Irf8 + Batf3 dependent (DC1) subset, and a CD8 - Irf4 + (DC2) subset. We found that the CD8 + DC1 subset can be further divided into CD8 + DC1a and CD8 +...
Saved in:
Published in | Frontiers in immunology Vol. 12; p. 746469 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
26.10.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1664-3224 1664-3224 |
DOI | 10.3389/fimmu.2021.746469 |
Cover
Summary: | Classical dendritic cells (cDCs) in mice have been divided into 2 major subsets based on the expression of nuclear transcription factors: a CD8
+
Irf8
+
Batf3 dependent (DC1) subset, and a CD8
-
Irf4
+
(DC2) subset. We found that the CD8
+
DC1 subset can be further divided into CD8
+
DC1a and CD8
+
DC1b subsets by differences in surface receptors, gene expression, and function. Whereas all 3 DC subsets can act alone to induce potent Th1 cytokine responses to class I and II MHC restricted peptides derived from ovalbumin (OVA) by OT-I and OT-II transgenic T cells, only the DC1b subset could effectively present glycolipid antigens to natural killer T (NKT) cells. Vaccination with OVA protein pulsed DC1b and DC2 cells were more effective in reducing the growth of the B16-OVA melanoma as compared to pulsed DC1a cells in wild type mice. In conclusion, the Batf3-/- dependent DC1 cells can be further divided into two subsets with different immune functional profiles
in vitro
and
in vivo
. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Antigen Presenting Cell Biology, a section of the journal Frontiers in Immunology Edited by: Daniel Saban, Duke University, United States Reviewed by: Luc Van Kaer, Vanderbilt University, United States; Joana Dias, Vaccine Research Center (NIAID), United States |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2021.746469 |